Civitas drug for Parkinson's symptom wins $1M grant

06/19/2013 | American City Business Journals

The Michael J. Fox Foundation for Parkinson's Research awarded Civitas Therapeutics a $1 million grant to support a Phase II study of CVT-301, its lead drug candidate for intermittent debilitating motor fluctuations, which affect many patients with Parkinson's disease. The drug is an inhaled formulation of levodopa, whose approved indications include OFF episodes.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC